HOOKIPA Pharma to Present at SVB Leerink’s CybeRx Series Vaccine Forum
September 16 2020 - 7:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will participate and
present at SVB Leerink’s CybeRx Series: Vaccine Forum, taking place
September 23 – 24, 2020:
- HOOKIPA Fireside Chat: Wednesday, September 23rd at
12:00 PM ET with Joern Aldag (CEO) and Igor
Matushansky (CMO)
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that reprograms the body’s
immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, non-replicating (VaxWave®) and replicating (TheraT®),
induce robust antigen-specific CD8+ T cells and
pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral
vectors target antigen presenting cells in vivo to activate the
immune system. Both technologies enable repeat administration to
augment and refresh immune responses. As a monotherapy, our
replicating arenavirus technology has the potential to induce CD8+
T cell response levels previously not achieved by other
immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial for patients awaiting kidney transplantation. To
expand its infectious disease portfolio, HOOKIPA entered into a
collaboration and licensing agreement with Gilead Sciences, Inc. to
research arenavirus-based functional cures for HIV and chronic
Hepatitis B infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201
was initiated in December 2019. The HB-202 IND application was
cleared by the FDA in June 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
For further information, please contact:
Media |
Investors |
Nina
Waibel |
Matt
Beck |
Senior
Director - Communications |
Executive
Director - Investor Relations |
nina.waibel@hookipapharma.com |
matthew.beck@hookipapharma.com |
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024